The clinical study is designed to evaluate the performance of NASARIX in adults with allergic rhinitis. NASARIX utilizes Polyrizon's proprietary Capture and Contain™ technology, which forms a ...
Guz Khan, Tez Ilyas, Kae Kurd, Aatif Nawaz, Prince Abdi, Ali Official, Smash Bengali, Riaad Moosa, and Mic Diesel join this year’s UK tour in support of orphan sponsorship programmes worldwide ...
LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce ...
CLINICAL TRIALS – PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer’s disease (#P055).
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data ...
Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder ...
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 ...
Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an ...
All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests; Four of five completed patients ...
A live and archived webcast of the events will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.
Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced ...
Jefferies Global Healthcare Conference November 16–19, 2026 London, United Kingdom Presentation Details: Fireside Chat with Mark Iwicki, CEO of Inhibikase and Dennis Ding, Jefferies Research on Monday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results